| Summary: | In over eighty years, despite successive antibiotics discoveries, the rapid advent of multidrug resistance among bacterial pathogens has jolted our misapprehension of success over them. Resistance is spreading faster than the discovery of new antibiotics/antimicrobials. Therefore, the search for better antimicrobials/additives becomes prudent. A water-soluble curcumin derivative (Cur<sub>aq</sub>) was synthesised, employing a Cu (I) catalysed 1, 3-cyclo addition reaction; it has been evaluated as a potential treatment for multidrug-resistant isolates and as an antibiotic adjuvant for meropenem against hypervirulent multidrug-resistant <i>Klebsiella pneumoniae</i> isolates. We also investigated its solubility and effect over carbapenemase activity. Additionally, we investigated its impact on the AcrAB-TolC system. We found that Cur<sub>aq</sub> inhibited bacterial growth at a minimal concentration of 16 µg/mL; at a 32 µg/mL concentration, it killed bacterial growth completely. Only nine (9.4%) <i>Klebsiella</i> isolates were sensitive to meropenem; however, after synergising with Cur<sub>aq</sub> (8 µg/mL), 85 (88.54%) hvKP isolates became sensitive to the drug. The Cur<sub>aq</sub> also inhibited the AcrAB-TolC efflux system at 1 µg/mL concentration by disrupting the membrane potential and causing depolarisation. The kinetic parameters obtained also indicated its promise as a carbapenemase inhibitor. These results suggest that Cur<sub>aq</sub> can be an excellent drug candidate as a broad-spectrum antibacterial and anti-efflux agent.
|
|---|